Operator
Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website. I will now turn the call over to Jennifer Williams, Investor Relations for Omeros.
Please go ahead.
Jennifer Williams
Thank you, and good afternoon, everyone. Before we begin, please note that today's discussion will include forward-looking statements.
These statements reflect management's current expectations and beliefs as of today and are subject to risks and uncertainties that could cause actual results to differ materially. For a detailed discussion of these risks and uncertainties, please refer to the special note regarding forward-looking statements and the Risk Factors sections in our quarterly report on Form 10-Q filed today with the SEC, as well as our most recent annual report on Form 10-K.
Today's call will also include a discussion of certain non-GAAP financial measures. A reconciliation of these non-GAAP measures to the corresponding GAAP measures is included in Omeros's earnings press release issued earlier today, which is available on the Investor Relations page of our website, and has been furnished with the Form 8-K we filed with the SEC earlier today.
With that, I'll turn the call over to Dr. Greg Demopulos, Chairman and CEO of Omeros.
Dr. Greg Demopulos
Thank you, Jennifer, and good afternoon, everyone. Joining me today are David Borges, our Chief Accounting Officer; Dr.
Catherine Melfi, our Chief Regulatory Officer; Dr. Steve Whitaker, Vice President of Clinical; and Bill Woodman, our Chief Commercial Officer.
I'll begin with an overview of our third quarter operations and financial results, followed by program updates. David will then review the financials in more detail, after which we'll open the call for questions.
Following FDA approval in December 2025, we launched Yartemlia in late January as the first and only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Yartemlia is also the first and only approved inhibitor of the lectin pathway of complement.
The third quarter marked just our second full quarter of Yartemlia sales, and we're pleased with our progress. In the third quarter, Yartemlia generated $41.8 million in gross sales and $35.9 million in net sales, reflecting continued commercial momentum.
Compared with the second quarter, gross sales increased 30%, and net sales increased 26%. As expected, gross-to-net deductions increased to 14% of gross sales from 11.5% in the second quarter, driven almost entirely by a substantial increase in 340B sales, consistent with our goals of increasing outpatient utilization of Yartemlia and expanding our customer base.
That momentum has continued into the fourth quarter, with Yartemlia revenues continuing to grow. As discussed in prior earnings calls, our reported GAAP financial results include mandatory, non-cash mark-to-market adjustments associated with the embedded derivative in our 2029 convertible notes.
A higher Omeros stock price increases the related non-cash expense. Reflecting these non-cash adjustments, GAAP net loss for the third quarter was $57.4 million, or 79 cents per share, compared to net income of $13.2 million, or 18 cents per share, in the second quarter.
Excluding the non-cash remeasurements of the embedded derivatives and other financial instruments, non-GAAP adjusted net income for the third quarter was $4.7 million, or 6 cents per share, compared to second quarter net income of $1.8 million, or 2 cents per share. We ended the third quarter with $95.3 million in cash and investments.
Most importantly, we generated $13.3 million in net cash from operating activities during the quarter, marking our second consecutive quarter of positive operating cash flow. As a reminder, in July we repurchased $30.5 million in aggregate principal amount of our 2029 convertible notes through two privately negotiated transactions for an aggregate of $60.2 million, reducing the outstanding principal amount by 43% to $40.3 million.
These transactions also reduced potential dilution by 4.9 million shares and eliminated $8.6 million in future interest payments. We achieved this reduction at a weighted average cost of $12.21 per underlying conversion share.
Including the repurchase of a little over 843,000 shares of common stock in the open market at $11.70 per share during the first half of 2026, we have reduced the number of outstanding or potentially issuable shares by 5.8 million year-to-date. Let's now look more closely at our Yartemlia launch.
As we have discussed before, our launch is focused on four priorities: one, educating transplant teams to recognize and treat TA-TMA earlier; two, securing institutional access through Pharmacy and Therapeutics, or P&T, committee approvals and streamlined ordering; three, ensuring timely and appropriate reimbursement and helping centers understand Yartemlia's reimbursement advantages over off-label therapies; and four, demonstrating Yartemlia's economic value through health economics and outcomes research, or HEOR. Through these four priorities, we continue our work to shift clinical practice toward proactive screening for TA-TMA rather than defaulting to a diagnosis of exclusion, and toward earlier identification and treatment of more patients, with the goal of improving outcomes.
To continue advancing these priorities, we have expanded our educational team by adding members to our Market Development Management and Medical Science Liaison teams. This expansion will further strengthen our field medical and educational capabilities and support scientific engagement with healthcare professionals across transplant centers nationwide.
In addition to physicians and pharmacists, we remain focused on supporting nurses. Nurses spend the most time with transplant patients and are often the first care team members to notice changes suggestive of TA-TMA.
For this reason, we recently established a clinical nurse educator team of six nurses from top-tier transplant centers. These Omeros nurses will work directly with nurses in transplant centers across the country.
Transplant centers have large nursing teams, and staff turnover, new hires, and rotating assignments create an ongoing need for training to reinforce recognition of the signs and symptoms of TA-TMA. Our nurse educators will help make TA-TMA awareness part of everyday transplant care, supporting more consistent identification and timely treatment with Yartemlia.
Across our nurse educators, Market Development Managers, and Medical Science Liaisons, we have added a total of 10 positions to our field force educational team. To further support our educational efforts, we are adding to our transplant physician, pharmacist, and nursing speaker programs by establishing a nephrology speaker bureau comprising both onconephrologists and general nephrologists.
Nephrologists are actively involved in the diagnosis and management of TA-TMA. Kidney disease is the most common form of organ dysfunction in TA-TMA.
Nephrologists are becoming increasingly well versed in the role of the lectin pathway, and we expect the Nephrology Speaker Bureau will meaningfully expand our educational reach while strengthening understanding of both Yartemlia and lectin pathway biology. Alongside these educational efforts, our field sales team is actively engaging all 175 U.S.
transplant centers. As of September 30, 109 unique accounts had ordered Yartemlia, a 49% increase from 73 accounts at June 30.
Following an outsized share of pediatric utilization in the first quarter, adult adoption accelerated in the second and third quarters. Adult patients now account for approximately 70% of utilization and pediatric patients for 30%.
This mix continues to move toward the historical nationwide allogeneic transplant mix of 85% adult and 15% pediatric procedures. As previously discussed, outpatient use of Yartemlia also increased this quarter, as evidenced by greater 340B participation.
This is good for patients, likely reflective of earlier treatment and potentially better outcomes. This is also good for transplant centers, given that reimbursement for approved drugs in the outpatient setting can range from average selling price, or ASP, plus 4.3% to ASP plus 10% or more.
P&T committee approvals also increased by 25% across transplant centers nationwide during the third quarter. By September 30, Yartemlia had received P&T committee approvals at 80% of the top 40 U.S.
transplant centers nationwide. Let's turn now to reimbursement and the payer experience.
To date, all appropriate claims of which we are aware have been paid by commercial payers, Medicare, or Medicaid, and coverage is fully aligned with the product label. Transplant centers are becoming increasingly aware of the New Technology Add-on Payment, or NTAP, for Yartemlia, which became effective on October 1.
The NTAP provides up to $287,000 in additional Medicare reimbursement per eligible inpatient case involving Yartemlia. This is particularly important because Medicare beneficiaries represent approximately 30% of all U.S.
allogeneic transplant recipients. No off-label treatment for TA-TMA, whether branded or biosimilar, has an NTAP.
This gives Yartemlia a distinct reimbursement advantage that can substantially reduce hospitals' net cost of treating eligible Medicare inpatients. Yartemlia's pass-through status also provides an important reimbursement advantage in the Medicare hospital outpatient setting.
The Centers for Medicare & Medicaid Services, or CMS, recently issued a new rule on 340B reimbursement. Beginning January 1, 2027, Medicare will generally reimburse affected hospitals for 340B-acquired drugs at average sales price, or ASP, minus 28%.
Drugs with transitional pass-through status, however, are exempt from this change and will continue to be reimbursed at ASP plus 6% or ASP plus 4.3% after sequestration. Neither branded eculizumab nor ravulizumab has pass-through status.
Yartemlia holds pass-through status through June 2029 and is therefore excluded from this reimbursement reduction. This preserves a substantial reimbursement advantage for Yartemlia over these branded off-label treatments when purchased under the 340B program and administered in affected Medicare hospital outpatient settings.
In the outpatient setting for commercially insured patients, Yartemlia's higher price per dose also translates into greater dollar margins per dose than lower-priced off-label alternatives, whether branded or biosimilar. We believe Yartemlia offers better efficacy and safety than off-label treatments for TA-TMA.
These reimbursement advantages provide centers with additional financial incentives to use Yartemlia in both inpatient and outpatient settings. Our HEOR manuscript is being finalized, with journal submission planned within the next few weeks.
The analyses show favorable incremental cost-effectiveness ratios, or ICERs, for Yartemlia compared to best supportive care, eculizumab, and ravulizumab. We expect that these analyses will further demonstrate Yartemlia's clinical and economic value, supporting its continued adoption.
The recognition of Yartemlia's importance to patients and the patient advocacy community is growing. In September, the National Organization for Rare Disorders, or NORD, honored Omeros with its 2026 Industry Innovation Award for Yartemlia.
NORD is the nation's leading rare disease patient advocacy organization. We are also preparing for a strong presence at the upcoming annual congress of the American Society of Hematology, a major international meeting for hematologists and transplant physicians.
Dr. Christine Duncan, Associate Professor at Harvard Medical School and senior physician at Dana-Farber Cancer Institute, will give a podium presentation on the consistent response to Yartemlia across three cohorts totaling 71 adult and pediatric patients with high-risk TA-TMA.
Omeros is also sponsoring a continuing medical education session titled Endothelial Injury, Complement, and TA-TMA After Allogeneic Stem Cell Transplant, chaired by Dr. Michelle Schoettler, Associate Professor at Emory University School of Medicine and a pediatric hematologist at Children's Healthcare of Atlanta.
The session will examine how TA-TMA has evolved from a historically underrecognized complication with limited treatment options to a disease with increasingly standardized diagnostic criteria, a clearer understanding of its complement biology, and now an FDA-approved therapy. The list of Yartemlia publications continues to expand.
Last month, in the journal Bone Marrow Transplantation, a group of international experts reported on a series of severely ill patients with high-risk TA-TMA, all of whom required intensive care unit stays. Responses to Yartemlia among these patients were remarkable.
Seven other manuscripts, associated and authored by transplant physicians, are in preparation or have been submitted, detailing similarly impressive responses to narsoplimab treatment in their patients, including the resolution of organ dysfunction and discontinuation of the need for dialysis. It's gratifying to see this growing body of evidence in both adult and pediatric TA-TMA, and supporting these publication efforts remains a corporate priority.
Increasing awareness and earlier identification of TA-TMA nationwide, spurred in part by our team's focused educational efforts and growing use and support of Yartemlia within the transplant care community, bode well for its adoption as standard of care. Alongside our U.S.
commercial efforts, we are diligently working to expand access internationally. Our initial focus was Europe.
As announced in October, the Committee for Medicinal Products for Human Use, or CHMP, following re-examination, which included meetings with CHMP and an ad hoc expert group, or AHEG, issued a negative opinion on our marketing authorization application for narsoplimab for the treatment of TA-TMA. CHMP's process and decision were disappointing and, from our perspective, misguided.
Separately, due to increasing demand for Yartemlia in the U.S. commercial market, we informed CHMP that after 10 years of supplying free drug to Europe and other regions globally under compassionate use, we intend to close the Yartemlia compassionate use program to new patients.
TA-TMA patients currently receiving Yartemlia through the program will be provided sufficient drug to complete their treatment courses. Our regulatory efforts are currently focused outside the European Union as we work to obtain near-term approvals for Yartemlia in TA-TMA across a number of other countries whose regulatory bodies recognize and can build upon the drug's FDA approval.
In parallel, we are working to make Yartemlia accessible internationally through fully reimbursed named patient programs in parts of Europe and other regions. While pursuing new markets for Yartemlia in TA-TMA, we are keenly focused on expanding its indications beyond TA-TMA.
Too often, Yartemlia is narrowly thought of as a TA-TMA therapeutic. That understates Yartemlia's potential, and here's why.
Endothelial injury is central to TA-TMA. Endothelial injury and other cellular damage directly activates the lectin pathway.
Yartemlia, as a lectin pathway inhibitor, has the potential to treat a wide spectrum of disorders driven by endothelial injury. These include other transplant-related disorders such as veno-occlusive disease, capillary leak syndrome, diffuse alveolar hemorrhage, and graft-versus-host disease.
There is substantial interest among transplanters to evaluate Yartemlia across these and other indications through investigator-initiated trials. To guide this expansion, we have built a new product planning team that brings insights from clinicians, health systems, payers, and patients into our pipeline strategy and related clinical investment decisions.
The three-person team will help identify development opportunities with the strongest clinical and commercial potential to build long-term shareholder value. Two open-label, single-arm clinical studies with historical controls evaluating Yartemlia are also slated to begin at the end of this year or early next, depending on the timing of institutional review board and ethics committee approvals.
One is in acute respiratory distress syndrome, or ARDS, in which endothelial injury is thought to be a key driver of disease. Mortality is high, and there currently is no good treatment for ARDS, which each year affects approximately 190,000 patients in the U.S.
alone. The study will assess Yartemlia in hyperinflammatory ARDS, which represents about 35% of all ARDS patients.
The second will assess Yartemlia's ability to prevent TA-TMA in high-risk pediatric transplant patients. Each study is designed to enroll approximately 50 to 60 patients.
Beyond Yartemlia, we are advancing the other assets in our MASP-2 platform: our Phase 2-ready, long-acting MASP-2 antibody, OMS1029, and our oral MASP-2 small molecule program. Both are well suited for chronic indications, with OMS1029 administered once quarterly intravenously or subcutaneously, and our oral agent targeting once-daily dosing.
Where possible, we target an orphan indication that includes a pediatric component as the first indication for a new molecule, potentially qualifying for a valuable rare pediatric priority review voucher upon FDA approval, subject to the program's eligibility and timing requirements. We are finalizing the initial Phase 2 indication for once-quarterly OMS1029, and clinical drug product and matching placebo have been manufactured and are available for Phase 2 clinical trials.
Moving on from our MASP-2 platform, we expect our MASP-3 inhibitor program, the other part of our complement franchise, to generate additional revenue soon. Our collaboration with Novo remains on track.
At the closing of the transaction in late 2025, we received an upfront payment of $240 million. In addition, we remain eligible for more than $1.8 billion in development and commercial milestones, including $100 million in near-term milestone payments, plus tiered royalties on net sales.
We continue to provide transition services to Novo at Novo's cost and expect to complete those services by mid-2027. In the meantime, we continue to advance our MASP-3 small molecule program toward the clinic.
Let's now turn to our pipeline programs beyond our complement inhibitor franchise. Our PDE7 inhibitor program evaluating OMS527 for cocaine use disorder remains fully funded by a grant from the National Institute on Drug Abuse, or NIDA.
Earlier this year, we met with FDA regarding the agency's request for additional nonclinical information before initiating the inpatient study in cocaine users. That nonclinical work is underway and expected to be completed this month.
The contract research organization conducting the nonclinical study faced delays in acquiring the study animals, we now expect to begin enrollment in the inpatient clinical trial in early 2027 following the upcoming holidays. We still expect data from the clinical trial in 2027.
Based on its mechanism of action and our extensive preclinical data, we believe that OMS527 could be effective across a wide range of addiction and compulsive disorders. Our targeted complement-activating therapy, or T-CAT, platform is a novel class of recombinant engineered antibodies designed to target and directly kill pathogens, including bacteria, fungi, viruses, and parasites.
These antibodies initiate complement activation directly on pathogen surfaces, thereby completely bypassing the classical pathway initiation complex, which pathogens typically exploit to escape immune clearance. Our initial focus is multidrug-resistant organisms, or MDROs, which pose a critical unmet medical need.
Unlike conventional antimicrobials, T-CAT is designed to eradicate pathogens regardless of resistance profile without promoting new drug resistance. In translationally relevant murine models of sepsis and pneumonia caused by multiple drug-resistant bacterial species, a single dose of the respective T-CAT monoclonal antibody demonstrated complete protection and bacterial clearance.
IND-enabling studies have begun, and we look forward to advancing T-CAT into the clinic. Lastly, Oncotox AML, or OMS805, is the lead program in our oncology platform.
OMS805 is an engineered biologic developed to treat acute myeloid leukemia, or AML, the most common and deadliest acute leukemia in adults. In both in vitro studies and studies in tumor-bearing animal models across a diverse range of human AML cell lines, OMS805 consistently demonstrated superior efficacy compared to current standard-of-care treatments.
This potent antitumor activity occurs even at very low doses and across mutations such as those in TP53 and FLT3, which historically have been associated with poor outcomes and treatment resistance. In immunocompetent nonhuman primates, a single course of Oncotox AML achieved a selective, reversible, and dose-dependent reduction in target myeloid progenitor cells by up to 99%.
Oncotox AML was well tolerated, demonstrating an encouraging safety profile that preserved essential hematopoietic stem cells without causing broader hematologic toxicity. To support upcoming clinical development, process engineering and initial clinical-scale manufacturing are already underway.
We have partnered with a leading contract biologics manufacturer to secure initial clinical drug supply and support clinical entry as IND-enabling studies conclude. Working with our advisory board of leading AML experts, we are preparing for a first-in-human trial targeted for late 2027.
As previously discussed, we are advancing OMS805 in stealth mode and do not plan to provide regular updates. We expect to announce the start of the Phase 1b trial and share clinical data when available.
That concludes our corporate and development program update. Before moving on to our financial discussion, I'd like to welcome Joe Shacken, who joined our Board of Directors and Audit Committee in August.
Joe brings decades of experience in investment banking, business leadership, and economic policy. He founded Seattle-based investment bank Broadmark Capital and co-founded and chaired publicly traded Broadmark Realty Capital.
A major contributor to the JOBS Act, Joe was also appointed by President Obama to the National Advisory Council on Innovation and Entrepreneurship. We look forward to benefiting from his capital markets expertise, his business experience, and his policy perspective.
Now with that, I'll turn the call over to David Borges, our Chief Accounting Officer, for a detailed discussion of our financial results. David?
David Borges
Thanks, Greg. Our third quarter results reflect continued progress in the commercial launch of Yartemlia, along with actions to strengthen our capital structure and enhance our financial flexibility.
Excluding non-cash remeasurement adjustments associated with our financial instruments, non-GAAP adjusted net income increased 161% from the second quarter, reflecting continued improvement in our financial performance. Yartemlia continued to demonstrate strong commercial momentum in the third quarter, with gross product revenues increasing to $41.8 million compared to $32.2 million in the second quarter.
Net product revenues increased to $35.9 million, up from $28.5 million in the second quarter. Gross-to-net adjustments were 14% in the third quarter, compared with 11.5% in the second quarter, and remained within our expectations.
These adjustments consisted primarily of chargebacks and distribution fees, with the increase driven primarily by higher utilization of the 340B program. Turning to our financial results, the net loss for the third quarter was $57.4 million, or 79 cents per share, compared to net income of $13.2 million, or 18 cents per share, in the second quarter.
Third quarter results included a $62 million non-cash mark-to-market loss on the financial instruments associated with our 2029 convertible notes, compared to an $11.5 million net non-cash gain in the second quarter, reflecting a $73.5 million swing in non-cash remeasurement. These adjustments were driven largely by increases in our stock price in the third quarter.
These non-cash adjustments do not affect our operating performance or liquidity and are excluded from our non-GAAP adjusted results. Excluding non-cash remeasurements of embedded derivatives and other financial instruments, non-GAAP adjusted net income for the third quarter was $4.7 million, or 6 cents per share, compared to $1.8 million, or 2 cents per share, for the second quarter.
In June and July, we entered into two privately negotiated transactions to repurchase $30.5 million aggregate principal amount of our 2029 convertible notes for $60.2 million plus accrued interest. Both transactions closed in July, reducing the outstanding principal by 43% from $70.8 million to $40.3 million.
These transactions also reduced future cash interest expense and potential dilution, with the number of shares issuable upon conversion declining from 11.4 million to 6.5 million. We may opportunistically repurchase additional notes in the future depending on market conditions and other considerations.
In connection with the second tranche of these repurchases involving $14.5 million in principal, we recorded a $1.9 million loss in the third quarter, reflecting the extinguishment of the repurchased notes and the associated embedded derivative liability. As of September 30, 2026, we had $95.3 million in cash and investments, and net cash provided by operations in the third quarter was $13.3 million.
Our cash balance reflects the $60.2 million paid to repurchase a portion of the 2029 convertible notes. Total operating expenses from continuing operations before interest and other income were $31.4 million, an increase of $3 million from the second quarter.
Under our transition services agreement with Novo, we continue to receive reimbursements for incurred costs, including third-party expenses and internal personnel costs. We also recognized $459,000 in reimbursements for zaltenibart inventory transferred during the quarter, which was recorded in other income.
Interest expense was $6.2 million, consisting primarily of the DRI royalty obligation and interest on the 2029 convertible notes. Excluding the Omidria royalty obligation to DRI, which is fully offset by amounts received from Rayner and therefore has no economic impact on Omeros, as well as non-cash amortization of debt issuance costs and discounts, contractual cash interest expense was $1.1 million.
This represents a decrease of $600,000 from the second quarter, reflecting the impact of our repurchases of the 2029 convertible notes. Interest and other income totaled $1.9 million in the third quarter.
Income from discontinued operations was $6.5 million in the third quarter, which was consistent with the second quarter. Because U.S.
Omidria royalties are passed directly to DRI, fluctuations in these payments have no impact on our cash position. Now let me turn to our expectations for the fourth quarter of 2026.
We expect total operating expenses from continuing operations to be slightly higher than in the third quarter. Research and development expenses are expected to increase, primarily due to higher spending on Yartemlia and our OMS805 Oncotox AML program.
Sales and marketing expenses also are expected to increase, reflecting continued investment in Yartemlia commercial infrastructure, marketing, and launch activities. Interest and other income is expected to increase in the fourth quarter, primarily reflecting anticipated inventory reimbursements from Novo.
Interest expense is expected to be approximately $6 million, reflecting the reduction in outstanding debt following the 2029 note repurchases. This estimate excludes potential non-cash adjustments related to the Omidria royalty obligation.
Income from discontinued operations is expected to be between $5 and $6 million, excluding non-cash remeasurement adjustments related to the Omidria contract royalty asset. Finally, our reported results will continue to reflect non-cash mark-to-market adjustments on the embedded derivative associated with our 2029 convertible notes.
Again, these adjustments can be volatile, driven primarily by changes in our stock price, and are excluded from our non-GAAP adjusted results. With that, I'll turn it back over to Greg.
Dr. Greg Demopulos
Thank you, David. Operator, would you please open the call for questions?
Operator
We will now begin the question-and-answer session. If you would like to ask a question, please raise your hand now.
The raise hand button can be found in the center of the toolbar at the bottom of your screen on Zoom desktop, and on the left side of the toolbar on Zoom mobile. If you have dialed in to today's call, please press star nine to raise your hand and star six to unmute.
Please stand by while we compile the Q&A roster. Your first question comes from Serge Belanger with Needham.
Your line is open, please go ahead.
Dr. Greg Demopulos
Hi, Serge. Hello?
Operator
Serge, a reminder to kindly unmute yourself.
Dr. Greg Demopulos
Operator, why don't we move on, and if Serge jumps back in the queue, happy to speak with him.
Operator
Your next question comes from the line of Olivia Saunders with Cantor Fitzgerald. Your line is open, please go ahead.
Olivia Saunders
Hi, good afternoon, thank you for the question. Just want to make sure you guys can hear me.
Dr. Greg Demopulos
Hi, Olivia. Yep, we can hear you.
Thank you.
Olivia Saunders
All right, perfect. Hoping to dig into the launch dynamics a little bit more, just given the acceleration that you saw last quarter versus this one.
Can you talk about the pace of adoption that you're expecting from here, and how are you thinking about how much utilization NTAP will actually drive in the fourth quarter? Anything you can say at this point around whether you're seeing a noticeable change in utilization or the pace of hospital adoption since that October 1st effective NTAP went into place?
Dr. Greg Demopulos
Yes, thanks. First, as we have said previously, we won't really be guiding to fourth quarter results other than I think to underscore what I said in the opening comments, which is that the momentum of growth has continued in Q4.
We are seeing continued growth in Q4. With respect to the impact of NTAP, it's interesting that NTAP, obviously important to us, obviously important to you as well, but it is interesting to us how physicians and frankly institutions aren't widely aware of the NTAP award for Yartemlia.
This is one of our current areas of focus, which is to make sure that that understanding of Yartemlia's receipt of NTAP and the importance to the inpatient facilities, and specifically Medicare patients, how that is important to those facilities as well. Bill, do you have any other comment you want to add on that about NTAP?
Bill Woodman
I have experience with NTAP with other companies and other drugs, and it is a learning process that you have to teach people on how to take advantage of that situation. We have a booth coming up here at ASH that will highlight the NTAP changes and what is available to these accounts.
It's interesting to note that the largest growth in allogeneic transplant is patients over 65. Actually at a recent meeting actually a couple days ago, they talked about the silver tsunami they're expecting to see as these treatments for AML in particular get better and better, then get more and more patients to transplant, and they expect to transplant more and more patients over 65.
NTAP is going to do nothing but help us as we move into that growth, and we're looking forward to educating as many people as we can to take advantage of this program.
Dr. Greg Demopulos
What we see is Medicare now representing about 30% of allogeneic transplants. We would expect, as Bill just said, that number to grow.
I think it's also important to recognize that while we're talking about a Medicare segment of the population, the allogeneic transplant population only, once again, that institutions, transplant centers, start using the drug for their Medicare patients, I expect that they will see the response, and that just causes continued expansion throughout each of those centers' transplant patients and TMA patients more broadly.
Olivia Saunders
Very helpful. Then if I could ask a follow-up on gross-to-net.
Where do you ultimately expect that to shake out as you shift patients to the outpatient setting moving forward?
Dr. Greg Demopulos
That's a great question. I don't think that we have shared a target number there, but I think that we are approaching it more quickly than we had anticipated approaching where we think that that cap will be.
I think that is reflective of the shift, obviously, given that this increase in gross-to-net is, as I said, almost exclusively due to 340B. This is a very encouraging signal to us of transfer from inpatient to outpatient.
Again, for us, as but just to make sure everybody understands, the 340B discount has no impact on our ASP. This is a government-mandated discount, not one that the company is taking independently.
It has no impact on our ASP, which overall then really just exemplifies, I think, the expansion from inpatient to outpatient, which, as I think we pointed out, benefits not only the patients, but the centers as well. I think that overall, Olivia, I would think, and again, I'm giving you a very soft number here, but somewhere in the high teens would be what we would think we might be approaching at some point.
To jump from 11.5% to 14% from the prior quarter to this quarter, we see as sort of a resounding acknowledgement, recognition, and of the importance of the drug and moving it into the outpatient setting. Also underscores, I think, the safety of the drug, certainly the perceived safety of the drug by the physicians, that they're willing to move this out of the inpatient setting where there is, as very regular constant monitoring, and into the outpatient setting.
I think it speaks really strongly for the potential of Yartemlia and the safety of Yartemlia from as well clearly of its efficacy. Did that help?
Olivia Saunders
That's great. Thank you, Greg.
Really appreciate that color.
Dr. Greg Demopulos
You're welcome, Olivia. Thank you.
Operator
Your next question comes from the line of Serge Belanger with Needham. Your line is open, please go ahead.
Serge Belanger
All right, good evening. Can you guys hear me now?
Dr. Greg Demopulos
We can. Hi, Serge, how are you?
Serge Belanger
I'm good, sorry, technically challenged. Anyway, I guess a couple questions on Yartemlia to start off with.
Can you maybe talk about the volume of vials in the in-patient setting versus the outpatient setting that you're currently seeing? Then secondly, just curious, what is the average price you estimate for on a per-patient basis?
Because I think in the past you've talked about some patients being treated on a weekly basis and some others on a twice-weekly basis. Just curious where that has settled and what kind of revenues you're seeing per patient on Yartemlia.
Dr. Greg Demopulos
Understood the question. We haven't shared the vial split between in- and outpatient, and so we won't today, other than to say that the outpatient use has meaningfully increased.
With respect to utilization per course, it's interesting. I think we're seeing a shift, and again, we don't have great access because of HIPAA and all of the confidentiality components around HIPAA, we don't have really great visibility into patient-level data, patient-level information, but what I think we are seeing is an increase in the use of twice-weekly early on, which, as we think about it and probably as you think about it, that probably ties to the increased outpatient use that we're seeing as well.
Hit them hard early and then move them to the outpatient setting, where you can treat them on an outpatient basis. The average use for our study and for our EAP were in the 8 to 10 vial per course range.
Having said that, I think we've noted before, we had some patients, primarily pediatric patients, who had remained on the drug for very long time, beyond a year. When we went to run that down to see why these patients had been kept on the drug for such a lengthy time, the question was, 'Gee, are you not seeing the response that you are hoping to see with the drug?'
The answer was quite the opposite, it's, 'No, drug's working great. This is why we have the patient on, and we're keeping the patient on, because we are concerned always about relapse.'
Obviously the fact that we were running this through the expanded access program where we were providing drug for free, I would expect had a very large impact on their ability to use it for that extensive amount of time. I think it does underscore that when one does, and this is what we hear from experts, I am only relaying what I'm hearing, but when we hear that the benefit-risk balance in the use of Yartemlia is so heavily weighted toward the benefit that a number of physicians are reticent to take their patients off Yartemlia simply because they want to keep them covered, protected in the event of a relapse.
I know I'm not answering your question specifically on what are the numbers. I can tell you that we don't have those tightly because those are really patient-level data that we just don't access, but I'm trying to give you some color, Serge, as to what we're hearing and what we're seeing.
Does that help?
Serge Belanger
Thank you. Maybe just one last one.
Looks like you have reimbursement and access more or less buttoned up here with the NTAP, the J-code, and some clarity with the 340B coverage. Just curious if you'll be in a position to provide guidance for 2027.
Dr. Greg Demopulos
We will begin providing guidance at some point in 2027, I expect. We just want to get a sense of how the overall sales are looking.
We're very pleased with what we're seeing, but what we don't want to do is get out ahead of ourselves and guide when we really don't have the data to back up that. It is one thing when estimates are provided by analysts like yourself and others, it's another thing when we provide those estimates and then those are viewed a little differently.
I'll ask Bill about his comments just on the utilization of the drug as well to see, Bill, if you have any other thoughts for Serge on utilization and vials per course?
Bill Woodman
I think that the biggest thing you can see is that that shift to the outpatient is the increase in our 340B discount. Whenever you launch in an acute disease, generally you get the sickest of the sick first.
The great thing about Yartemlia is it works. They're treating the sickest sick on the inpatient side, they get more comfortable with it, those patients leave the ICU, they go home, they get treated in their outpatient center, and you can see that shift as we go from quarter to quarter, and it's going to get nothing but better from there.
We have many, many examples of people walking out of ICUs that they didn't expect to happen. The good news is the drug is working.
That shift over time, as Greg alluded to, will probably increase as people get more and more comfortable with it. We've had situations where people have gone home to just their regular community-basis hospital and continued to receive treatment, and that hospital is not a transplant center and have had no problem infusing, billing for, getting paid for the drug.
All these things are good signs to see that we're going to treat more and more patients in the outpatient side, and as people get really comfortable with it, they'll treat on the outpatient side before they come in, and you'll get a more consistent basis over time as you treat those patients before they get into trouble. Right now we're really treating the patients who are already in trouble, and we want to move that to the outpatient side.
Dr. Greg Demopulos
Thanks, Bill, once we have a better sense of all of those factors that Bill just touched on, we'll be more comfortable providing guidance. Until then, really, we're still sifting through data, as you are.
All I can say is the data that we see, all of the data that we see, are highly encouraging for the potential of Yartemlia in TA-TMA.
Bill Woodman
From a marketing perspective, we grew in every metric that we measure. We can't be happier.
The momentum is easy to see and feel, especially at recent medical meetings. We're built for the long-term sustained growth, and we're going to ensure to invest in ways that this education occurs, and people are more ready to treat these patients as quickly as possible.
Dr. Greg Demopulos
I think that's underscored by just the focus that we went through in the prepared comments about the number of educator positions that we've added. We've added 10 positions in the last six weeks, and this is not driven by a concern that we're not educating enough, it's driven by the customer requests and customer need for the education.
We're not trying to fix a problem by adding these educators, we're addressing a need that's being voiced by the transplant physicians, pharmacists, nurses, the end users or the end-use administrators of the drug, and I think that's an important distinction.
Operator
Your final question comes from the line of Steve Brozak with WBB. Your line is open, please go ahead.
Steve Brozak
Hey, thanks for taking the question. Actually, I do have two.
Just to reiterate, you are not just cash flow breakeven, you actually are cash flow positive right now. I guess you can repeat anything you've got, because the only question becomes on the treatment of the derivative, when do you expect that, by the way, to clear up?
Then I've got a really significant question to ask.
Dr. Greg Demopulos
I'll start with the last question first. As soon as we get rid of the convert overhang, which we've taken a large part of that away through the repurchase of the converts, but however we eliminate the remainder of that convert, that derivative will disappear with it.
With respect to your question about cash flow positive, yes. We're $13.3 million cash flow positive from operations this quarter.
Frankly, we were also cash flow positive last quarter in our first full quarter of the launch, which we think is pretty remarkable. We don't frankly expect that, I know we've said we won't guide for Q4, but I think it's pretty clear that we don't expect that's going to change in Q4.
This is where we stand, and this is how we're able to continue funding all of the other things that we're doing with the company. That and what we expect will be the revenues coming from the Novo transaction.
All of this, I think, puts us in a very strong financial position across the company. David, any other comments on that, or color you want to add?
David Borges
No, I would echo what you said. We've seen a nice path from 4.1 of cash from ops in Q2 to over 13 this quarter, and see that trend continuing going forward, as you said.
Yep.
Dr. Greg Demopulos
As we move really to what we expect will be standard of care, at some point that threshold is reached, and the use of the drug just, I think, will increase even more so. That again is my personal view.
Steve Brozak
That brings me to a perfect segue here. 30 years ago, I worked on a private transaction and a public offering for a company called Alexion, and just about 20 years ago—
Dr. Greg Demopulos
Never heard of them.
Steve Brozak
Good, just keep to that. They came up with a product, eculizumab, a complement product obviously, and I'm sure you've looked at what they did and how they grew their revenue.
How would you compare your approach with what they did? Because obviously it's a good historical mark.
Not saying it's identical, but it's a good historical mark. I'll jump back in the queue with that open question, how's that?
Dr. Greg Demopulos
Look, I understand the question. I understand, I think, the relevance of it and the curiosity about it.
Remember that these were very different products, right? When Soliris, or eculizumab, was launched, that initial indication was for PNH, paroxysmal nocturnal hemoglobinuria, which is a chronic disease.
What we are treating is TA-TMA, which is an acute disease, duration of therapy obviously limited. One is we're treating until we cure the patient, which is, to the best of our knowledge, relatively quickly, and eculizumab was used chronically, treating effectively for that patient's life.
The pricing, we have looked at that, obviously we looked at that as we were determining where to price Yartemlia. The course of therapy for a year pretty similar, ours probably less, as you might imagine, for an acute or episodic treatment versus chronic.
There are real differences there, Steve, but having said that, I think as you may have anticipated, certainly we've looked at that. The eculizumab numbers aren't readily available for U.S., they sort of need to be implied from the worldwide sales, but for third quarter of their sales versus third quarter of our sales, our sales U.S.
only, we exceed their third quarter worldwide sales. At least I think that's my understanding, Bill, is that correct?
Bill Woodman
That's correct, yeah.
Dr. Greg Demopulos
Yep. Then when you look at the first three quarters of sales again implied in the U.S.
based on subsequent splits, we're in the U.S., we're doing about 60% better in that revenues than they did in their third quarter. We're pleased with how we're stacking up.
That does not in any way predict, guide what we're going to do in the future, but obviously we're happy with where we stand. I think, yeah, your question was an interesting one.
Of course we look at these things. We don't only look at eculizumab, we look really at all complement inhibitors.
That includes pegcetacoplan, or Empaveli, that includes even Ravu, and it also includes defibrotide. We have a pretty good set of metrics against which to assess ourselves and Yartemlia's growth and uptake, and I think we're quite pleased with it, particularly given what I said about chronic versus episodic use.
I don't know, I'm guessing that answered your question, but if not, do you—
Steve Brozak
Oh, no, no, it does. They say history doesn't repeat itself, but it does rhyme, you've answered it.
Thank you.
Dr. Greg Demopulos
Good. Thank you.
Operator
There are no further questions at this time. I will now turn the call back to Dr.
Demopulos for closing remarks.
Dr. Greg Demopulos
Thank you, operator, and thanks, everyone, for your time. Yartemlia's approval really turned years of scientific work into a treatment for patients who urgently needed one.
Its adoption is now helping fund, as we discussed, the next chapter of that work: extending its reach and advancing therapies for other serious diseases. We're excited about Yartemlia's expanding potential, and confident in our science and our team's ability to develop new medicines that improve patients' lives and build lasting value for our shareholders.
Thank you again, all, for joining us this afternoon and for your continued support. We look forward to speaking with you again.
Thank you.
Operator
This concludes today's call. Thank you for attending.
You may now disconnect.